According to the research report, the global hepatology market size is expected to touch USD 40.22 Billion by 2032, from USD 13.02 Billion in 2022, growing with a significant CAGR of 11.94% from 2023 to 2032.
Key Takeaways:
- North America is expected to dominate the hepatology market during the forecast period.
- By treatment type, the antiviral drugs segment is expected to be the dominating segment throughout the forecast period.
- By disease type, the hepatitis segment is expected to be the leading segment of the market. On the other hand, the liver cancer segment will grow at a significant rate during the forecast period.
The hepatology report offers a comprehensive study of the current state expected at the major drivers, market strategies, and key vendors’ growth. The report presents energetic visions to conclude and study the market size, market hopes, and competitive surroundings. The research also focuses on the important achievements of the market, research & development, and regional growth of the leading competitors operating in the market. The current trends of the global hepatology in conjunction with the geographical landscape of this vertical have also been included in this report.
The report offers intricate dynamics about different aspects of the global hepatology market, which aids companies operating in the market in making strategic development decisions. The study also elaborates on significant changes that are highly anticipated to configure growth of the global hepatology during the forecast period. It also includes a key indicator assessment that highlights growth prospects of this market and estimates statistics related to growth of the market in terms of value (US$ Mn) and volume (tons).
Sample Link @ https://www.precedenceresearch.com/sample/3186
This study covers a detailed segmentation of the global hepatology market, along with key information and a competition outlook. The report mentions company profiles of players that are currently dominating the global hepatology market, wherein various developments, expansions, and winning strategies practiced and implemented by leading players have been presented in detail.
Key Players
- Astellas Pharma Inc.
- Merck & Co. Inc.
- Abbott Laboratories
- Bristol- Myers Squibb
- AbbVie Inc.
- Emergent BioSolutions Inc.
- F. Hoffmann- La Roche AG
- Eli Lilly and Company
- Viatris Inc.
- Gilead Sciences, Inc.
Market Segmentation
By Treatment Type
- Antiviral Drugs
- Vaccines
- Immunosuppressants
- Targeted Therapy
- Chemotherapy
- Corticosteroids
- Immunoglobulins
By Disease Type
- Hepatitis
- Liver Cancer
- Genetic Disorders
- Autoimmune Diseases
- Non- Alcoholic Fatty Liver Diseases
- Others
By Geography
- North America
- Europe
- Asia-Pacific
- Latin America
- Middle East and Africa
Research Methodology
The research methodology adopted by analysts for compiling the global hepatology report is based on detailed primary as well as secondary research. With the help of in-depth insights of the market-affiliated information that is obtained and legitimated by market-admissible resources, analysts have offered riveting observations and authentic forecasts for the global market.
During the primary research phase, analysts interviewed market stakeholders, investors, brand managers, vice presidents, and sales and marketing managers. Based on data obtained through interviews of genuine resources, analysts have emphasized the changing scenario of the global market.
For secondary research, analysts scrutinized numerous annual report publications, white papers, market association publications, and company websites to obtain the necessary understanding of the global hepatology market.
TABLE OF CONTENT
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology (Premium Insights)
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. COVID 19 Impact on Hepatology Market
5.1. COVID-19 Landscape: Hepatology Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
Chapter 6. Market Dynamics Analysis and Trends
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
Chapter 7. Competitive Landscape
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
Chapter 8. Global Hepatology Market, By Treatment Type
8.1. Hepatology Market, by Treatment Type, 2023-2032
8.1.1. Antiviral Drugs
8.1.1.1. Market Revenue and Forecast (2020-2032)
8.1.2. Vaccines
8.1.2.1. Market Revenue and Forecast (2020-2032)
8.1.3. Immunosuppressants
8.1.3.1. Market Revenue and Forecast (2020-2032)
8.1.4. Targeted Therapy
8.1.4.1. Market Revenue and Forecast (2020-2032)
8.1.5. Chemotherapy
8.1.5.1. Market Revenue and Forecast (2020-2032)
8.1.6. Corticosteroids
8.1.6.1. Market Revenue and Forecast (2020-2032)
8.1.7. Immunoglobulins
8.1.7.1. Market Revenue and Forecast (2020-2032)
Chapter 9. Global Hepatology Market, By Disease Type
9.1. Hepatology Market, by Disease Type, 2023-2032
9.1.1. Hepatitis
9.1.1.1. Market Revenue and Forecast (2020-2032)
9.1.2. Liver Cancer
9.1.2.1. Market Revenue and Forecast (2020-2032)
9.1.3. Genetic Disorders
9.1.3.1. Market Revenue and Forecast (2020-2032)
9.1.4. Autoimmune Diseases
9.1.4.1. Market Revenue and Forecast (2020-2032)
9.1.5. Non- Alcoholic Fatty Liver Diseases
9.1.5.1. Market Revenue and Forecast (2020-2032)
9.1.6. Others
9.1.6.1. Market Revenue and Forecast (2020-2032)
Chapter 10. Global Hepatology Market, Regional Estimates and Trend Forecast
10.1. North America
10.1.1. Market Revenue and Forecast, by Treatment Type (2020-2032)
10.1.2. Market Revenue and Forecast, by Disease Type (2020-2032)
10.1.3. U.S.
10.1.3.1. Market Revenue and Forecast, by Treatment Type (2020-2032)
10.1.3.2. Market Revenue and Forecast, by Disease Type (2020-2032)
10.1.4. Rest of North America
10.1.4.1. Market Revenue and Forecast, by Treatment Type (2020-2032)
10.1.4.2. Market Revenue and Forecast, by Disease Type (2020-2032)
10.2. Europe
10.2.1. Market Revenue and Forecast, by Treatment Type (2020-2032)
10.2.2. Market Revenue and Forecast, by Disease Type (2020-2032)
10.2.3. UK
10.2.3.1. Market Revenue and Forecast, by Treatment Type (2020-2032)
10.2.3.2. Market Revenue and Forecast, by Disease Type (2020-2032)
10.2.4. Germany
10.2.4.1. Market Revenue and Forecast, by Treatment Type (2020-2032)
10.2.4.2. Market Revenue and Forecast, by Disease Type (2020-2032)
10.2.5. France
10.2.5.1. Market Revenue and Forecast, by Treatment Type (2020-2032)
10.2.5.2. Market Revenue and Forecast, by Disease Type (2020-2032)
10.2.6. Rest of Europe
10.2.6.1. Market Revenue and Forecast, by Treatment Type (2020-2032)
10.2.6.2. Market Revenue and Forecast, by Disease Type (2020-2032)
10.3. APAC
10.3.1. Market Revenue and Forecast, by Treatment Type (2020-2032)
10.3.2. Market Revenue and Forecast, by Disease Type (2020-2032)
10.3.3. India
10.3.3.1. Market Revenue and Forecast, by Treatment Type (2020-2032)
10.3.3.2. Market Revenue and Forecast, by Disease Type (2020-2032)
10.3.4. China
10.3.4.1. Market Revenue and Forecast, by Treatment Type (2020-2032)
10.3.4.2. Market Revenue and Forecast, by Disease Type (2020-2032)
10.3.5. Japan
10.3.5.1. Market Revenue and Forecast, by Treatment Type (2020-2032)
10.3.5.2. Market Revenue and Forecast, by Disease Type (2020-2032)
10.3.6. Rest of APAC
10.3.6.1. Market Revenue and Forecast, by Treatment Type (2020-2032)
10.3.6.2. Market Revenue and Forecast, by Disease Type (2020-2032)
10.4. MEA
10.4.1. Market Revenue and Forecast, by Treatment Type (2020-2032)
10.4.2. Market Revenue and Forecast, by Disease Type (2020-2032)
10.4.3. GCC
10.4.3.1. Market Revenue and Forecast, by Treatment Type (2020-2032)
10.4.3.2. Market Revenue and Forecast, by Disease Type (2020-2032)
10.4.4. North Africa
10.4.4.1. Market Revenue and Forecast, by Treatment Type (2020-2032)
10.4.4.2. Market Revenue and Forecast, by Disease Type (2020-2032)
10.4.5. South Africa
10.4.5.1. Market Revenue and Forecast, by Treatment Type (2020-2032)
10.4.5.2. Market Revenue and Forecast, by Disease Type (2020-2032)
10.4.6. Rest of MEA
10.4.6.1. Market Revenue and Forecast, by Treatment Type (2020-2032)
10.4.6.2. Market Revenue and Forecast, by Disease Type (2020-2032)
10.5. Latin America
10.5.1. Market Revenue and Forecast, by Treatment Type (2020-2032)
10.5.2. Market Revenue and Forecast, by Disease Type (2020-2032)
10.5.3. Brazil
10.5.3.1. Market Revenue and Forecast, by Treatment Type (2020-2032)
10.5.3.2. Market Revenue and Forecast, by Disease Type (2020-2032)
10.5.4. Rest of LATAM
10.5.4.1. Market Revenue and Forecast, by Treatment Type (2020-2032)
10.5.4.2. Market Revenue and Forecast, by Disease Type (2020-2032)
Chapter 11. Company Profiles
11.1. Astellas Pharma Inc.
11.1.1. Company Overview
11.1.2. Product Offerings
11.1.3. Financial Performance
11.1.4. Recent Initiatives
11.2. Merck & Co. Inc.
11.2.1. Company Overview
11.2.2. Product Offerings
11.2.3. Financial Performance
11.2.4. Recent Initiatives
11.3. Abbott Laboratories
11.3.1. Company Overview
11.3.2. Product Offerings
11.3.3. Financial Performance
11.3.4. Recent Initiatives
11.4. Bristol- Myers Squibb
11.4.1. Company Overview
11.4.2. Product Offerings
11.4.3. Financial Performance
11.4.4. Recent Initiatives
11.5. AbbVie Inc.
11.5.1. Company Overview
11.5.2. Product Offerings
11.5.3. Financial Performance
11.5.4. Recent Initiatives
11.6. Emergent BioSolutions Inc.
11.6.1. Company Overview
11.6.2. Product Offerings
11.6.3. Financial Performance
11.6.4. Recent Initiatives
11.7. F. Hoffmann- La Roche AG
11.7.1. Company Overview
11.7.2. Product Offerings
11.7.3. Financial Performance
11.7.4. Recent Initiatives
11.8. Eli Lilly and Company
11.8.1. Company Overview
11.8.2. Product Offerings
11.8.3. Financial Performance
11.8.4. Recent Initiatives
11.9. Viatris Inc.
11.9.1. Company Overview
11.9.2. Product Offerings
11.9.3. Financial Performance
11.9.4. Recent Initiatives
11.10. Gilead Sciences, Inc.
11.10.1. Company Overview
11.10.2. Product Offerings
11.10.3. Financial Performance
11.10.4. Recent Initiatives
Chapter 12. Research Methodology
12.1. Primary Research
12.2. Secondary Research
12.3. Assumptions
Chapter 13. Appendix
13.1. About Us
13.2. Glossary of Terms
Contact Us:
Precedence Research
Apt 1408 1785 Riverside Drive Ottawa, ON, K1G 3T7, Canada
Call: +1 774 402 6168
Email: sales@precedenceresearch.com
Website: https://www.precedenceresearch.com
Blog: https://www.pharma-geek.com
0 Comments